Tumour-targeted nanomedicines
Author Information
Author(s): Lammers T, Hennink W E, Storm G
Primary Institution: Utrecht Institute for Pharmaceutical Sciences, Utrecht University
Conclusion
Tumour-targeted nanomedicines can significantly improve the therapeutic index of anticancer agents by enhancing drug delivery to tumor sites and reducing toxicity to normal tissues.
Supporting Evidence
- Nanomedicines can enhance drug levels at tumor sites through passive targeting.
- Liposomal formulations have shown improved pharmacokinetics and reduced toxicity.
- Active targeting strategies are being developed to improve drug delivery to cancer cells.
Takeaway
This study talks about tiny medicine carriers that help deliver cancer drugs directly to tumors, making them work better and causing less harm to healthy parts of the body.
Methodology
The review summarizes various tumour-targeted nanomedicine systems and strategies, discusses their clinical status, and highlights future directions.
Limitations
The review does not provide original experimental data and is limited to summarizing existing literature.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website